Roche Holding AG
ROG: XSWX (CHE)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
CHF 745.00 | Gkwy | Tjrwtmrvr |
Roche: Looking Past COVID-19 Headwinds and TIGIT Uncertainty, Portfolio Appears Solid
We're maintaining our CHF 419/$57 fair value estimates for Roche following first-quarter sales results in line with our expectations, as growth benefited from strong sales of newer products like ophthalmology drug Vabysmo and rare disease drug Evrysdi as well as fading biosimilar headwinds, although foreign exchange and COVID-19 headwinds pushed reported sales to a 7% decline.